Last shipments of mecasermin for amyotrophic lateral sclerosis will be sent to Treatment IND patients at the end of December. The T-IND stopped enrolling late in 1998; 159 of the original 400 patients selected by lottery for the trial remain on drug. Cephalon is trying to get an FDA waiver to allow it to send a several month supply to patients in its last shipment. A Nov. 19 letter to patients and prescribers cited "the inability of the companies to bear the expense of the program without a reasonable prospect of near-term approval." A Phase III trial conducted by Japanese partner Kyowa Hakko Kogyo has been completed and Cephalon has met with FDA concerning what efficacy analyses would be required to support licensure of the "potentially approvable" drug
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth